VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients.

被引：0
|
作者：
Colado, Enrique [1 ]
Mateos, Maria-Victoria [1 ]
Moreno, Maria-Jose
Dearriba, Felipe
de la Rubia, Javier
Lahuerta, Juan Jose [2 ]
Iniesta, Pastora
Viguria, Maria Cruz
Gonzalez, Ana Pilar
Garcia-Sanz, Ramon [1 ]
Olazabal, Juan [1 ]
Miguel, Jesus F. San [1 ]
机构：
[1] Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1265 / 1266
页数：2
相关论文
共 50 条
  • [21] Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Dmide
    Cavalli, Maide
    Ria, Roberto
    Gentilini, Silvia
    Patriarca, Francesca
    Nozzoli, Chiara
    Levi, Anna
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Vincelli, Donatella
    Baldini, Luca
    Morabito, Fortunato
    Grasso, Mariella
    Marasca, Roberto
    Rizzo, Manuela
    Pautasso, Chiara
    Falcone, Antonietta Pia
    Gottardi, Daniela
    Montefusco, Vittorio
    Musolino, Caterina
    Cangialosi, Clotilde
    Mansueto, Giovanna
    Liberati, Anna Marina
    Magarotto, Valeria
    Omede, Paola
    Musto, Pellegrino
    Petrucci, Maria Teresa
    Boccadoro, Mario
    BLOOD, 2012, 120 (21)
  • [22] Bortezomib (Velcade™) observational study in China -: Efficacy and safety of bortezomib based regimen in 223 relapsed or refractory multiple myeloma patients
    Shen, Zhi-xiang
    BLOOD, 2007, 110 (11) : 282B - 283B
  • [23] Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
    Offidani, Massimo
    Polloni, Claudia
    Cavallo, Federica
    Liberati, Anna Marina
    Ballanti, Stelvio
    Pulini, Stefano
    Catarini, Massimo
    Alesiani, Francesco
    Corvatta, Laura
    Gentili, Silvia
    Caraffa, Patrizia
    Boccadoro, Mario
    Leoni, Pietro
    Palumbo, Antonio
    LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1722 - 1727
  • [24] A phase I/II trial on melphalan, prednisone, thalidomide and defribotide combination in relapsed/refractory multiple myeloma patients
    Palumbo, Antonio
    Larocca, Alessandra
    Rus, Cecilia
    Gay, Francesca
    Rossi, Davide
    Pregno, Patrizia
    Falco, Patrizia
    Avonto, Ilaria
    Magarotto, Valeria
    Cavallo, Federica
    Iacobelli, Massimo
    Gaidano, Gianluca
    Mitsiades, Constantine
    Richardson, Paul G.
    Anderson, Kenneth C.
    Boccadoro, Mario
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [25] Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
    Morabito, Fortunato
    Bringhen, Sara
    Larocca, Alessandra
    Wijermans, Pierre
    Victoria Mateos, Maria
    Gimsing, Peter
    Mazzone, Carla
    Gottardi, Daniela
    Omede, Paola
    Zweegman, Sonja
    Jose Lahuerta, Juan
    Zambello, Renato
    Musto, Pellegrino
    Magarotto, Valeria
    Schaafsma, Martijn
    Oriol, Albert
    Juliusson, Gunnar
    Cerrato, Chiara
    Catalano, Lucio
    Gentile, Massimo
    Isabel Turel, Ana
    Liberati, Anna Marina
    Cavalli, Maide
    Rossi, Davide
    Passera, Roberto
    Rosso, Stefano
    Beksac, Meral
    Cavo, Michele
    Waage, Anders
    San Miguel, Jesus
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    Offidani, Massimo
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 355 - 362
  • [26] Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients
    Ciolli, S
    Leoni, F
    Gigli, F
    Rigacci, L
    Bosi, A
    LEUKEMIA & LYMPHOMA, 2006, 47 (01) : 171 - 173
  • [27] Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
    Azarm, Taleb
    Akbari, Mojtaba
    Azarm, Arezo
    Mohager, Hamid
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2012, 17 (01): : 8 - 14
  • [28] CLNICAL EFFICACY OF VEL-CTD (BORTEZOMIB, CYCLOPHOSPHAMIDE, THALIDOMIDE, AND DEXAMETHASONE) REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE II STUDY
    Kim, Y. K.
    Ahn, J. S.
    Yang, D. H.
    Sohn, S. K.
    Moon, J. H.
    Kim, H. J.
    Shin, H. J.
    Chung, J. S.
    Choi, Y. J.
    Chae, Y. S.
    Kim, J. G.
    Lee, J. H.
    Lee, J. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 383 - 383
  • [29] Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
    Kim, Yeo-Kyeoung
    Sohn, Sang-Kyun
    Lee, Jae-Hoon
    Yang, Deok-Hwan
    Moon, Joon-Ho
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    ANNALS OF HEMATOLOGY, 2010, 89 (05) : 475 - 482
  • [30] Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
    Yeo-Kyeoung Kim
    Sang-Kyun Sohn
    Jae-Hoon Lee
    Deok-Hwan Yang
    Joon-Ho Moon
    Jae-Sook Ahn
    Hyeoung-Joon Kim
    Je-Jung Lee
    Annals of Hematology, 2010, 89 : 475 - 482
12345